Skip to main content

Inmune Bio Inc.

corporate_fare Company Profile

Inmune Bio Inc.

INMB·NASDAQ·Life Sciences·CIK 0001711754

INmune Bio is a clinical-stage biotechnology company that develops and sells product candidates designed to reprogram the innate immune system. The company focuses on diseases where chronic inflammation and immune dysfunction are key drivers. Its main focus is treating Recessive Dystrophic Epidermolysis Bullosa (RDEB), a severe pediatric orphan disease, using CORDStrom™. CORDStrom is a proprietary platform derived from pooled human umbilical cord mesenchymal stromal cells. RDEB is caused by mutations in the COL7A1 gene, leading to skin blistering, chronic non-healing wounds, difficulty swallowing, and failure to thrive. The chronic inflammation in RDEB often progresses to fatal squamous cell carcinoma. Currently, there are no approved systemic treatments for RDEB; existing approved products are topical and do not address the systemic issues that CORDStrom targets. CORDStrom has completed a pivotal, blinded, randomized cross-over trial. Beyond RDEB, the company is advancing two other clinical-stage platforms. XPro1595 (XPro) is a protein therapeutic that targets neuroinflammation by neutralizing soluble TNF. XPro has completed Phase I and Phase II clinical trials for Alzheimer's Disease (AD) in the United Kingdom, the European Union, Australia, and Canada. INKmune™ is a natural killer (NK) cell-priming platform designed to use a patient's own immune system to eliminate cancer cells. The INKmune program is nearing completion of an open-label Phase II trial for metastatic castrate-resistant prostate cancer (mCRPC).

Inmune Bio Inc. (NASDAQ:INMB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for INMB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for INMB spans 424B5, 8-K, 10-Q.

Recent high-impact activity:

  • INmune Bio Trims Q3 Loss to $4.7M, Sets Full UK Filing for February 2027
  • Inmune Bio Prices $4.5M Stock Sale at $1.50 With Matching Warrant Package
  • $4.5M Direct Offering Priced at $1.50 a Share, 6% Below Market
  • Inmune Bio Signs Uniphar Commercial Pact, Pulls UK MAA Filing Forward to Feb 2027
  • Ebstrocel UK Filing Accelerated to Feb 2027, Approval Targeted Mid-2027

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
50K
Net Income
-45.93M
Diluted EPS
-1.86
Op. Cash Flow
-22.58M
Free Cash Flow
-23.62M
Operating Income
-47.38M
Cash & Equivalents
24.75M
Debt / Equity
0.00×
Net Margin
-918.66×
Shares Outstanding
26.59M sh
Source: 10-K · filed 2026-03-30 · accession 0001213900-26-036370

Short Interest & Short Volume

14.40 days to cover

FINRA reported short interest of 2,658,847 shares in INMB as of the October 30, 2026 settlement, a 7.9% decrease from the prior period — about 14.4 days to cover at its recent average daily volume. On November 20, 2026, 43.1% of INMB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,658,847 shares as of October 30, 2026
Change vs prior period▼ 7.9%
Days to cover14.40 at avg daily volume of 184,693
Daily short volume (FINRA facilities)43.1% of 190,311 shares on November 20, 2026
5-day average short volume60.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for INMB, detected from its recent SEC filings · based on capital-structure filings through 2026-10-29.

1 recent capital raise1 shelf registration

Priced $4.5M Stock and Warrant Deal · Net Proceeds About $4.0 Million

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with I →
$0.8103 -2.02% today
52-week range · as of 2026-10-29 $0.8103 – $2.6
Market cap
$25.6M
Volume
327.1K (0.9× avg)
3-mo avg 358.1K
Live data · 2026-11-22 12:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed INMB - Latest Insights

INMB
Nov 05, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.18
Real-time Price: $0.8103 info
Change: -$0.3647 (-31%) info
Market Cap: $25.603M info
INMB
Oct 29, 2026, 7:30 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $0.8103 info
Change: -$0.7097 (-47%) info
Market Cap: $25.603M info
INMB
Oct 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $0.8103 info
Change: -$0.5997 (-43%) info
Market Cap: $25.603M info
INMB
Oct 21, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.69
Real-time Price: $0.8103 info
Change: -$0.8787 (-52%) info
Market Cap: $25.603M info
INMB
Oct 21, 2026, 7:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $0.8103 info
Change: -$0.8197 (-50%) info
Market Cap: $25.603M info
INMB
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $2.03
Real-time Price: $0.8103 info
Change: -$1.22 (-60%) info
Market Cap: $25.603M info
INMB
Aug 06, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.88
Real-time Price: $0.8103 info
Change: -$1.07 (-57%) info
Market Cap: $25.603M info
INMB
Jul 31, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.77
Real-time Price: $0.8103 info
Change: -$0.9547 (-54%) info
Market Cap: $25.603M info
INMB
Jul 20, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.84
Real-time Price: $0.8103 info
Change: -$1.03 (-56%) info
Market Cap: $25.603M info
INMB
Jul 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.79
Real-time Price: $0.8103 info
Change: -$0.9797 (-55%) info
Market Cap: $25.603M info
INMB
Jul 01, 2026, 7:23 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.67
Real-time Price: $0.8103 info
Change: -$0.8547 (-51%) info
Market Cap: $25.603M info
INMB
Jul 01, 2026, 7:16 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.63
Real-time Price: $0.8103 info
Change: -$0.8197 (-50%) info
Market Cap: $25.603M info
INMB
Jul 01, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.61
Real-time Price: $0.8103 info
Change: -$0.7997 (-50%) info
Market Cap: $25.603M info
INMB
Jun 25, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.49
Real-time Price: $0.8103 info
Change: -$0.6832 (-46%) info
Market Cap: $25.603M info
INMB
Jun 23, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.42
Real-time Price: $0.8103 info
Change: -$0.6097 (-43%) info
Market Cap: $25.603M info
INMB
Jun 23, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.42
Real-time Price: $0.8103 info
Change: -$0.6097 (-43%) info
Market Cap: $25.603M info
INMB
Jun 17, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.30
Real-time Price: $0.8103 info
Change: -$0.4897 (-38%) info
Market Cap: $25.603M info
INMB
Jun 02, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.42
Real-time Price: $0.8103 info
Change: -$0.6097 (-43%) info
Market Cap: $25.603M info
INMB
Jun 02, 2026, 8:05 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1.45
Real-time Price: $0.8103 info
Change: -$0.6397 (-44%) info
Market Cap: $25.603M info
INMB
May 14, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.60
Real-time Price: $0.8103 info
Change: -$0.7883 (-49%) info
Market Cap: $25.603M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets